Reference : Circulating erythropoietin levels after bone marrow transplantation: inappropriate re...
Scientific journals : Article
Human health sciences : Hematology
http://hdl.handle.net/2268/6265
Circulating erythropoietin levels after bone marrow transplantation: inappropriate response to anemia in allogeneic transplants.
English
Beguin, Yves mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
Clemons, G. K. [> > > >]
Oris, Renée [Centre Hospitalier Universitaire de Liège - CHU > > Chimie médicale >]
Fillet, Georges mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
1991
Blood
American Society of Hematology
77
4
868-73
Yes (verified by ORBi)
International
0006-4971
1528-0020
Washington
DC
[en] Adolescent ; Adult ; Anemia/blood ; Bone Marrow Transplantation/adverse effects ; Child ; Child, Preschool ; Cytomegalovirus Infections/blood/etiology ; Erythropoietin/blood ; Female ; Graft Survival ; Graft vs Host Disease/blood ; Hematocrit ; Hematologic Diseases/surgery ; Humans ; Male ; Middle Aged ; Transplantation, Autologous ; Transplantation, Homologous
[en] We studied 24 recipients of autologous bone marrow transplantation (ABMT) or allogeneic BMT (BMT) to determine whether impaired erythropoietin (Epo) response to anemia could delay full erythropoietic recovery. Observed Epo levels were compared with predicted levels based on the relationship between Epo and hematocrit in 125 control subjects. Circulating Epo levels were normal during conditioning and the early posttransplant period. Between days 21 and 180, Epo levels remained normal in ABMT patients but were inappropriately low for the degree of anemia in BMT patients. Median time to full erythropoietic engraftment was longer in BMT than in ABMT recipients. Circulating Epo returned to appropriate levels after day 180, except in patients with active cytomegalovirus infection. We conclude that impaired Epo response to anemia can contribute to delayed erythropoietic recovery after allogenic BMT. Renal toxicity of ciclosporin, interaction between host and donor marrow, and cytomegalovirus infection might play a role. This study could support the use of recombinant human Epo to accelerate erythropoietic engraftment after BMT.
http://hdl.handle.net/2268/6265

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Beguin-Blood 1991.pdfPublisher postprint677.52 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.